India's navy launches submarine, warships to guard against China's presence in Indian Ocean
UK inflation unexpectedly eases in December, which could reduce pressure in bond markets
Body count from South African mine siege rises to 60
Question on ASEAN stumped Hegseth at Senate hearing. What is it and why is it important?
US importers rush in goods from China as Trump tariff threat looms
Novak Djokovic breaks a tie with Roger Federer for the most Grand Slam matches in tennis history
China's RedNote: what you need to know about the app TikTok users are flocking to
British author Neil Gaiman denies ever engaging in non-consensual sex as more accusers come forward
ZURICH (Reuters) - Swiss contract drug manufacturer Lonza said on Wednesday it has signed an agreement to acquire the Genentech manufacturing facility in Vacaville, California, from drugmaker Roche for $1.2 billion in cash.
Lonza plans to invest around 500 million Swiss francs ($562.30 million) to upgrade the facility and enhance capabilities at the site to accommodate the next generation of mammalian biologics therapies, the company said in a statement.
($1 = 0.8892 Swiss francs)
(Reporting by Dave Graham; Editing by Miranda Murray)
